What does Astrotech Corporation do?
Astrotech Corporation is a small Nasdaq-listed instrumentation and technology-commercialization company. It uses a shared analytical platform—the Astrotech Mass Spectrometer Technology, or AMS Technology—to build application-specific subsidiaries. Its purpose is to simplify calibration, ruggedize components, and move laboratory-grade chemical identification into high-volume field environments, a positioning central to the official Astrotech product strategy.
How is the company structured?
Astrotech Technologies owns and licenses the core intellectual property, while subsidiaries adapt it to separate use cases. One platform can therefore support security, industrial, agricultural, environmental, and medical concepts, but each market brings different buyers, sales cycles, certifications, and competitors.
What problem is the platform trying to solve?
Traditional mass spectrometers offer precise molecular identification but are often laboratory-centered and specialist-dependent. Astrotech argues that automated calibration, simpler interfaces, ruggedized hardware, and application-specific sampling can move that precision to the decision point: security alarms, contamination sites, or production lines.
| Business unit | Primary product or platform | Target customer | Commercial status |
|---|---|---|---|
| 1st Detect | TRACER 1000 ETD and NTD | Aviation, cargo, government, corrections, security operators | Commercial deployments; certification remains a major growth gate |
| EN-SCAN | Labrador HH-GC and environmental GC-MS tools | Environmental consultants, industrial sites, remediation teams | Product launch and early deployment phase |
| AgLAB | AgLAB 1000 series | Agricultural processors and distillation operators | Early commercialization |
| Pro-Control | Pro-Control 1000 | Chemical and industrial manufacturers | Development and commercialization stage |
How does Astrotech make money?
Astrotech is not yet a scaled recurring-revenue instrument company. Revenue is episodic, led by 1st Detect product activity and supplemented by consumables, warranty, training, and government work. The fiscal 2025 Form 10-K explains that equipment contracts can contain multiple performance obligations, while government milestones may be recognized under percentage-of-completion accounting.
What are the revenue streams?
| Revenue source | Economic character | Margin implication | Key dependency |
|---|---|---|---|
| Devices | Large, irregular orders | Can improve gross profit when production volume and mix are favorable | Certifications, procurement budgets, customer validation, channel execution |
| Consumables | Potentially recurring installed-base revenue | Attractive only if pricing exceeds material and service cost | Active utilization of deployed instruments |
| Warranty and training | Support revenue tied to devices | Can smooth revenue but remains small at current scale | Installed-base growth and customer retention |
| Grant and contract revenue | Milestone-based development funding | Can offset R&D spending but may carry project-specific costs | Government awards, milestone execution, allowable-cost accounting |
Why does customer concentration matter?
Four material customers accounted for substantially all of Astrotech's $1.0 million of fiscal 2025 revenue, compared with three material customers accounting for substantially all of fiscal 2024 revenue. That concentration means one delayed shipment, failed qualification, or procurement pause can materially change a quarter. It also explains why a single $429,000 order for six TRACER 1000 explosive trace detectors was strategically important in fiscal 2025: the order represented roughly 41% of full-year revenue.
The model becomes more attractive only if placements create follow-on consumables, service, and upgrades. Until then, Astrotech is closer to a commercialization-stage project portfolio than a predictable instruments franchise.
What did Astrotech's latest quarter show?
The newest complete financial package covers the quarter ended March 31, 2026, Astrotech's third quarter of fiscal 2026. The fiscal 2026 third-quarter Form 10-Q shows a company that reduced development expense but still generated revenue far below its operating-cost base.
What changed in Q3 FY2026?
| Metric | Q3 FY2026 | Q3 FY2025 | Interpretation |
|---|---|---|---|
| Revenue | $0.343M | $0.534M | Down 35.8%, mainly from lower product revenue and negative grant adjustments |
| Gross profit | $0.067M | $0.237M | Lower device mix and consumables sold below cost compressed profitability |
| SG&A | $2.085M | $2.115M | Approximately flat despite the revenue decline |
| R&D | $1.435M | $1.989M | Down $0.554M, or 27.9%, as spending shifted toward sales activity |
| Operating loss | $(3.453)M | $(3.867)M | Improved because expense reductions exceeded the gross-profit decline |
| Net loss per share | $(2.25) | $(2.18) | Other expense offset part of the operating improvement |
What does the nine-month picture say about cash conversion?
For the nine months ended March 31, 2026, revenue was $0.787 million, gross profit was $0.262 million, and the gross margin was 33%. SG&A of $5.941 million and R&D of $5.211 million produced a $10.890 million operating loss. Net cash used in operating activities was $11.165 million, while capital expenditures were $0.857 million. Operating cash flow minus capital expenditures was approximately negative $12.022 million for the nine-month period.
The accompanying Q3 FY2026 earnings release emphasized 37 TRACER locations in 16 countries and a shift from development toward saleable products. Those operating milestones are directionally positive, but the financial evidence still shows an early commercialization phase.
How do FY2025 economics frame the investment case?
Fiscal 2025 provides the cleanest full-year baseline. Revenue fell 37.0% to $1.049 million as 1st Detect sold fewer devices. Gross margin held near 45%, but higher R&D widened the net loss and continued cash consumption.
What does the annual income statement reveal?
| Metric | FY2025 | FY2024 | Analytical reading |
|---|---|---|---|
| Revenue | $1.049M | $1.664M | Commercial volume remains too low for trend stability |
| Gross margin | 45.3% | 45.1% | Product economics can be positive before corporate costs |
| SG&A | $7.067M | $7.241M | Corporate cost was relatively stable |
| R&D | $8.142M | $6.790M | Up 19.9% as multiple platforms advanced |
| Operating cash flow | $(12.952)M | $(9.725)M | Cash burn increased faster than commercial revenue |
| Capital expenditures | $0.833M | $0.579M | Physical investment is modest relative to operating burn |
The value-chain issue is clear: Astrotech has invested in intellectual property, engineering, certification, and product readiness, but sales conversion, distribution, recurring consumables, service density, and installed-base utilization have not reached economic scale.
Which turning points shaped Astrotech's current strategy?
Astrotech's history shows how a space-heritage company became a field-instrument platform and why management continues to pursue adjacent markets.
-
1984The company was organized in Delaware. Its long operating history and spaceflight heritage created engineering experience, but the present economics are driven by analytical instruments rather than legacy space services.
-
2007Thomas B. Pickens III became chairman and chief executive officer. The long tenure concentrates strategic continuity and makes leadership judgment particularly important.
-
2019The TRACER 1000 received European Civil Aviation Conference certification, opening sales to customers that accept ECAC standards and validating mass spectrometry for trace detection.
-
2024The TSA placed the TRACER 1000 on the Air Cargo Security Technology List and advanced it to Stage II testing, creating a route into U.S. air-cargo operations.
-
January 20251st Detect received a Department of Homeland Security research contract to mature next-generation explosives trace detection, adding external validation and grant revenue.
-
2025Astrotech launched EN-SCAN, introduced the enhanced TRACER 1000 NTD, completed a six-device TSA-approved order, and placed the first NTD system in Vietnam.
-
May 2026The TRACER 1000 achieved ECAC/EU G1 approval, while EN-SCAN launched the Labrador handheld gas chromatograph. These events moved two product families closer to broader selling activity.
-
May 2026The board approved a lunar resource and infrastructure initiative. It reconnects Astrotech with its space heritage, but it is an early strategic option rather than a current operating segment or revenue source.
The latest certification is described in the company's May 2026 ECAC/EU G1 announcement. Regulatory acceptance is part of the product: certification expands the buyer set, reduces procurement risk, and can convert technical performance into commercial permission.
What gives Astrotech a competitive advantage—and what limits it?
Where could the technology create differentiation?
Astrotech argues that mass-spectrometry trace detection offers a broader threat library, stronger molecular identification, lower false-alarm potential, and better uptime than incumbent ion-mobility systems. In industrial and environmental applications, the proposed advantage is placing defensible chemical data with field personnel without waiting for a central laboratory.
Who are the main competitors and substitutes?
The company does not publish a complete competitor list for every application. Its fiscal 2025 filing identifies ABB, Siemens, Emerson, Thermo Fisher Scientific, Endress+Hauser, PerkinElmer, Mettler Toledo, PAC, Horiba Process Analyzers, and AMETEK as legacy original-equipment manufacturers relevant to industrial analysis. In security, the practical competitive benchmark is the installed base of IMS-based trace detectors. For EN-SCAN, the substitute is often the existing workflow of sample collection, transport, and off-site laboratory analysis.
| Arena | Competitive set or substitute | Astrotech differentiation | Constraint |
|---|---|---|---|
| Security trace detection | Installed IMS-based ETDs | Expandable library and molecular specificity | Qualification cycles, procurement conservatism, service expectations |
| Industrial process analysis | Large automation and analytical OEMs | Simplified MS nearer to the factory process | Customer integration, reliability proof, incumbent distribution |
| Environmental testing | Central laboratories and portable field analyzers | Immediate on-site VOC identification and quantification | Method acceptance, operator training, price-to-workflow value |
| Agricultural processing | Manual sampling and conventional process controls | Real-time chemistry feedback intended to improve yield | Small target base, regulatory variability, customer ROI proof |
The official EN-SCAN page captures the strategic promise: laboratory-grade environmental intelligence at the point of decision. The investor question is whether that promise produces repeatable sales rather than isolated demonstrations.
How strong are Astrotech's liquidity and capital runway?
What did the March 2026 balance sheet contain?
At March 31, 2026, Astrotech held $2.679 million of cash and cash equivalents and $3.903 million of short-term investments. Combined liquid financial assets were therefore $6.582 million. Current assets were $11.329 million, current liabilities were $1.835 million, working capital was approximately $9.5 million, total assets were $16.173 million, and stockholders' equity was $12.155 million.
Why is financing and dilution a central issue?
The nine-month operating cash outflow of $11.165 million exceeded the March 2026 cash-and-investments balance. That is not a precise runway forecast, but it demonstrates why external capital is strategically important. Astrotech entered an at-the-market agreement on June 2, 2026 that permitted sales of up to $24.493 million of common stock. The related Form 8-K states that the agent receives a 3.0% commission on gross proceeds sold.
A June 2026 shelf registration contemplated up to $200 million of securities over time. This is issuance capacity, not cash received. For valuation, the correct focus is net cash actually raised, quarterly burn after cost actions, the share count after each financing period, and whether proceeds fund measurable commercial milestones.
Who owns ASTC stock, and how is the company governed?
How much influence does management have?
The latest proxy reported 1,769,269 common shares outstanding on October 16, 2025. Thomas B. Pickens III beneficially owned 222,507 shares, or 12.6%, including common stock, restricted stock, and exercisable options under the proxy's methodology. All directors and executive officers as a group beneficially owned 294,968 shares, or 16.8%. This is meaningful insider alignment, not majority control.
| Holder or group | Beneficial ownership | Percent of class | Why it matters |
|---|---|---|---|
| Thomas B. Pickens III | 222,507 shares | 12.6% | Long-tenured CEO and chairman has substantial economic exposure and strategic influence |
| Directors and executive officers | 294,968 shares | 16.8% | Insider incentives are material relative to the small public float |
| Series D preferred stock | 280,898 preferred shares outstanding | Non-voting in ordinary matters | Has conversion and protective rights that add capital-structure complexity |
| Board independence | 5 directors identified as independent | Not applicable | Audit, compensation, and governance oversight is assigned to independent directors |
The figures come from the 2025 proxy statement. Options, restricted stock, preferred conversion rights, the rights plan, and future issuance can all change voting and economic exposure.
What governance signals deserve attention?
Pickens has served as chairman and CEO since January 2007. Five directors are independent under Nasdaq rules. Scott Bartley became interim chief financial officer in October 2025, and Nihanth Badugu became chief operating officer in August 2025, emphasizing execution and commercialization.
Which opportunities, risks, and KPIs matter most?
Where could the growth case improve?
The clearest opportunity is converting regulatory progress into repeat orders. ECAC/EU G1 approval broadens aviation access, while TSA checkpoint qualification could open a larger U.S. market. More placements could support consumables and service. EN-SCAN could become a second engine if field results displace laboratory delay. The company's lunar initiative adds optionality but remains separate from the near-term instrument business.
What could weaken the story?
The main risks are adoption, regulatory timing, funding, and execution across too many applications. The units have limited histories and face larger competitors with established service networks. Approvals may be delayed or lost, customer concentration magnifies volatility, and intellectual-property disputes or licensing needs could consume capital. Supply chains, tariffs, cybersecurity, and a small technical workforce add pressure.
Which variables matter most in a DCF or comparable-company analysis?
A steady-state DCF is fragile when free cash flow is deeply negative and annual revenue is below $2 million. A more disciplined approach separates existing liquidity from the operating business, models product families by probability and timing, and explicitly incorporates future financing. Comparable multiples should also be used cautiously: established analytical-instrument companies have recurring service revenue, broader installed bases, and positive margins that Astrotech has not yet demonstrated.
| Valuation driver | Current evidence | What would improve the model | Downside sensitivity |
|---|---|---|---|
| Revenue scale | $1.049M in FY2025; $0.787M in the first nine months of FY2026 | Repeat multi-unit orders and recurring installed-base revenue | Long procurement cycles and order concentration |
| Gross margin | 45.3% in FY2025; 20% in Q3 FY2026 | Higher device volume, favorable mix, consumables priced above cost | Low-volume manufacturing and grant-cost volatility |
| Operating leverage | $15.209M FY2025 operating expense | Revenue growth without proportional SG&A and R&D growth | Multiple subsidiaries sustain parallel cost structures |
| Financing | ATM capacity and rising share count in June 2026 | Capital raised at attractive prices tied to clear milestones | Dilution before commercial proof |
| Terminal economics | Not yet established | Service, consumables, certification advantages, and customer retention | Technology remains a project portfolio rather than a franchise |
What is the key takeaway from Astrotech analysis?
Astrotech is commercializing one platform across security, environmental, industrial, agricultural, and exploratory space markets. ECAC certification, TSA air-cargo approval, a DHS contract, deployments in 16 countries, and product launches are real proof points, but they have not yet produced scale economics.
The financial tension is unusually clear. Astrotech generated $1.049 million of revenue in fiscal 2025 and $0.787 million in the first nine months of fiscal 2026, while operating expenses remained above $11 million in that nine-month period. Liquidity and financing therefore matter almost as much as technology. Management must convert certification and pipeline activity into repeated device orders, improve gross-margin consistency, build recurring consumables and service revenue, and reduce cash burn before dilution becomes the dominant source of value transfer.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.